Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.71
ARAY's Cash to Debt is ranked lower than
68% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ARAY: 0.71 )
Ranked among companies with meaningful Cash to Debt only.
ARAY' s 10-Year Cash to Debt Range
Min: 0.71  Med: 10000.00 Max: No Debt
Current: 0.71
Equity to Asset 0.16
ARAY's Equity to Asset is ranked lower than
92% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ARAY: 0.16 )
Ranked among companies with meaningful Equity to Asset only.
ARAY' s 10-Year Equity to Asset Range
Min: -1.98  Med: 0.22 Max: 0.65
Current: 0.16
-1.98
0.65
F-Score: 2
Z-Score: 0.64
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -5.05
ARAY's Operating margin (%) is ranked lower than
61% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. ARAY: -5.05 )
Ranked among companies with meaningful Operating margin (%) only.
ARAY' s 10-Year Operating margin (%) Range
Min: -586.2  Med: -12.52 Max: 1.28
Current: -5.05
-586.2
1.28
Net-margin (%) -10.59
ARAY's Net-margin (%) is ranked lower than
62% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ARAY: -10.59 )
Ranked among companies with meaningful Net-margin (%) only.
ARAY' s 10-Year Net-margin (%) Range
Min: -584.5  Med: -12.00 Max: 2.56
Current: -10.59
-584.5
2.56
ROE (%) -49.37
ARAY's ROE (%) is ranked lower than
79% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ARAY: -49.37 )
Ranked among companies with meaningful ROE (%) only.
ARAY' s 10-Year ROE (%) Range
Min: -68.25  Med: -25.19 Max: 4.2
Current: -49.37
-68.25
4.2
ROA (%) -8.53
ARAY's ROA (%) is ranked lower than
59% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. ARAY: -8.53 )
Ranked among companies with meaningful ROA (%) only.
ARAY' s 10-Year ROA (%) Range
Min: -72.32  Med: -8.33 Max: 1.72
Current: -8.53
-72.32
1.72
ROC (Joel Greenblatt) (%) -33.89
ARAY's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. ARAY: -33.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -381.56  Med: -43.82 Max: 31.27
Current: -33.89
-381.56
31.27
Revenue Growth (3Y)(%) -5.60
ARAY's Revenue Growth (3Y)(%) is ranked higher than
72% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ARAY: -5.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARAY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7  Med: 6.30 Max: 133.5
Current: -5.6
-7
133.5
EBITDA Growth (3Y)(%) -100.00
ARAY's EBITDA Growth (3Y)(%) is ranked lower than
219% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ARAY: -100.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARAY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 6.90 Max: 50.4
Current: -100
0
50.4
EPS Growth (3Y)(%) -20.40
ARAY's EPS Growth (3Y)(%) is ranked higher than
52% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ARAY: -20.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARAY' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.4  Med: 11.30 Max: 91.3
Current: -20.4
-20.4
91.3
» ARAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ARAY Guru Trades in Q3 2014

Paul Tudor Jones 36,179 sh (New)
Jim Simons 1,312,023 sh (+147.96%)
Steven Cohen 1,277,500 sh (+24.16%)
PRIMECAP Management 8,665,700 sh (-0.29%)
Chuck Royce 1,658,500 sh (-1.89%)
» More
Q4 2014

ARAY Guru Trades in Q4 2014

Chuck Royce 1,713,000 sh (+3.29%)
PRIMECAP Management 8,665,700 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 992,983 sh (-24.32%)
Steven Cohen 952,100 sh (-25.47%)
» More
Q1 2015

ARAY Guru Trades in Q1 2015

Chuck Royce 2,046,500 sh (+19.47%)
Steven Cohen 1,123,200 sh (+17.97%)
PRIMECAP Management 8,495,700 sh (-1.96%)
Jim Simons 447,700 sh (-54.91%)
» More
Q2 2015

ARAY Guru Trades in Q2 2015

Paul Tudor Jones 44,869 sh (New)
Jim Simons 1,130,652 sh (+152.55%)
PRIMECAP Management 8,603,700 sh (+1.27%)
Steven Cohen Sold Out
Chuck Royce 1,997,500 sh (-2.39%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 62.50
ARAY's Forward P/E is ranked lower than
85% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. ARAY: 62.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.95
ARAY's P/B is ranked lower than
84% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. ARAY: 6.95 )
Ranked among companies with meaningful P/B only.
ARAY' s 10-Year P/B Range
Min: 1.1  Med: 2.98 Max: 11.5
Current: 6.95
1.1
11.5
P/S 1.38
ARAY's P/S is ranked higher than
69% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ARAY: 1.38 )
Ranked among companies with meaningful P/S only.
ARAY' s 10-Year P/S Range
Min: 0.81  Med: 1.70 Max: 5.99
Current: 1.38
0.81
5.99
EV-to-EBIT -30.53
ARAY's EV-to-EBIT is ranked lower than
242% of the 159 Companies
in the Global Medical Devices industry.

( Industry Median: 21.34 vs. ARAY: -30.53 )
Ranked among companies with meaningful EV-to-EBIT only.
ARAY' s 10-Year EV-to-EBIT Range
Min: -623.5  Med: -26.80 Max: 802.9
Current: -30.53
-623.5
802.9
Current Ratio 2.09
ARAY's Current Ratio is ranked lower than
57% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ARAY: 2.09 )
Ranked among companies with meaningful Current Ratio only.
ARAY' s 10-Year Current Ratio Range
Min: 0.94  Med: 1.82 Max: 2.75
Current: 2.09
0.94
2.75
Quick Ratio 1.46
ARAY's Quick Ratio is ranked lower than
64% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ARAY: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
ARAY' s 10-Year Quick Ratio Range
Min: 0.78  Med: 1.46 Max: 2.43
Current: 1.46
0.78
2.43
Days Inventory 158.24
ARAY's Days Inventory is ranked lower than
60% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. ARAY: 158.24 )
Ranked among companies with meaningful Days Inventory only.
ARAY' s 10-Year Days Inventory Range
Min: 70.63  Med: 109.34 Max: 199.92
Current: 158.24
70.63
199.92
Days Sales Outstanding 72.00
ARAY's Days Sales Outstanding is ranked higher than
65% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. ARAY: 72.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARAY' s 10-Year Days Sales Outstanding Range
Min: 26.26  Med: 64.06 Max: 101.57
Current: 72
26.26
101.57

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 222.00
ARAY's Price/Tangible Book is ranked lower than
100% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. ARAY: 222.00 )
Ranked among companies with meaningful Price/Tangible Book only.
ARAY' s 10-Year Price/Tangible Book Range
Min: 2.35  Med: 5.68 Max: 224.67
Current: 222
2.35
224.67
Price/Median PS Value 0.81
ARAY's Price/Median PS Value is ranked higher than
69% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ARAY: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
ARAY' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.06 Max: 3.27
Current: 0.81
0.69
3.27
Earnings Yield (Greenblatt) (%) -3.28
ARAY's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. ARAY: -3.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARAY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.31  Med: 0.90 Max: 2.9
Current: -3.28
-3.31
2.9

Analyst Estimate

Jun16 Jun17
Revenue(Mil) 410 459
EPS($) -0.32 -0.06
EPS without NRI($) -0.32 -0.06

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XEJ.Germany,
Accuray Inc was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. The Company's technologies are designed specifically to deliver precise radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, and image guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat a wide range of cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws.
» More Articles for ARAY

Headlines

Articles On GuruFocus.com
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CEO Buys Highlight: SONS, OPK, AKS, ARAY, ENH Nov 09 2014 
Weekly CEO Buys Highlight: JMP, SONS, OPK, ARAY, CBNJ Nov 04 2014 
Accuray: Leading the Field Of Radiosurgery Jul 24 2014 
comment on ARAY May 12 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
comment on ARAY May 10 2013 
Weekly CEO Buys Highlight: AGNC, WTSLA, ARAY, FSC, SREV Feb 19 2013 

More From Other Websites
ACCURAY INC Financials Sep 02 2015
Accuray to Participate in the Morgan Stanley Global Healthcare Conference 2015 Sep 01 2015
ACCURAY INC Files SEC form 10-K, Annual Report Aug 28 2015
Accuray Gains on Order Growth & 21st Century Oncology Deal Aug 24 2015
Accuray (ARAY) Looks Good: Stock Moves 12.7% Higher Aug 24 2015
Accuray's Q4 Loss Wider than Expected, Gross Orders Surge Aug 21 2015
Accuray (ARAY) Stock Climbs on 21st Century Oncology Order Aug 21 2015
Accuray Awarded Multi-System Order by 21st Century Oncology Aug 21 2015
Edited Transcript of ARAY earnings conference call or presentation 20-Aug-15 8:30pm GMT Aug 20 2015
Accuray reports 4Q loss Aug 20 2015
Accuray reports 4Q loss Aug 20 2015
Accuray To Report Fiscal 2015 Fourth Quarter and Full Year Financial Results On August 20, 2015 Aug 20 2015
Accuray Inc Earnings Call scheduled for 4:30 pm ET today Aug 20 2015
ACCURAY INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 20 2015
Accuray Generates 14% Year-Over-Year Gross Order Growth During Fourth Quarter Aug 20 2015
Q4 2015 Accuray Inc Earnings Release - After Market Close Aug 20 2015
Accuray draws calls before report Aug 10 2015
Accuray To Report Fiscal 2015 Fourth Quarter and Full Year Financial Results On August 20, 2015 Aug 03 2015
Accuray Products Received Highest Composite User Satisfaction Ratings in Latest MD Buyline Report Jul 27 2015
Accuray Products Received Highest Composite User Satisfaction Ratings in Latest MD Buyline Report Jul 27 2015
Accuray (ARAY) Products Post Positive Clinical Results - Analyst Blog Jul 15 2015
Accuray, RaySearch Laboratories Ink RayCare Agreement - Analyst Blog Jul 14 2015
New TomoTherapy® System Data Presented at Leading Scientific Industry Meeting Jul 14 2015
New CyberKnife® System Data Presented at Leading Scientific Industry Meeting Jul 14 2015
New TomoTherapy® System Data Presented at Leading Scientific Industry Meeting Jul 14 2015
New CyberKnife® System Data Presented at Leading Scientific Industry Meeting Jul 14 2015
Accuray and RaySearch Announce Long-Term Collaboration Agreement Regarding the RayCare® Oncology... Jul 13 2015
Accuray and RaySearch Announce Long-Term Collaboration Agreement Regarding the RayCare® Oncology... Jul 13 2015
Accuray slides in late trading after cutting revenue outlook Apr 30 2015
Accuray reports 3Q loss Apr 30 2015
Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software Apr 30 2015
Accuray Reports Financial Results for Third Quarter of Fiscal Year 2015 Apr 30 2015
Accuray To Report Results For Third Quarter Fiscal 2015 On April 30, 2015 Apr 09 2015
Accuray and Christie InnoMed Sign Exclusive Sales Agent Agreements for Radiation Therapy Systems in... Mar 05 2015
Class A User Licenses for Accuray Products Awarded to 16 Hospitals in China Feb 17 2015
Accuray Reports Financial Results for Second Quarter of Fiscal Year 2015 Feb 11 2015
Accuray reports 2Q loss Jan 27 2015
Accuray To Report Results For Second Quarter Fiscal 2015 On January 27, 2015 Jan 12 2015
Accuray to Participate in Brean Capital's 2014 Life Science Conference Nov 10 2014
Accuray misses Street 1Q forecasts Oct 30 2014
Accuray Reports Financial Results for First Quarter of Fiscal Year 2015 Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK